Ivonescimab is under clinical development by Akeso and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ivonescimab LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ivonescimab overview

Ivonescimab (AK-112) is under development for the treatment of solid tumors like renal cell carcinoma, triple-negative breast cancer, small-cell lung cancer, hepatocellular carcinoma and squamous and non-squamous non-small cell lung cancer, recurrent or metastatic cervical squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma, recurrent or metastatic biliary tract cancers, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, recurrent or metastatic pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), colorectal cancer, metastatic colorectal cancer, non-small cell lung cancer, small-cell lung cancer, sarcomas and recurrent or metastatic head And neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The therapeutic candidate is a bi-specific antibody targeting programmed cell death protein 1 (PD-1) and VEGF. It is administered through intravenous and intravenous drip route. It is developed based on antibody analytical (ACE) platform.

Akeso overview

Akeso is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also offers kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China

For a complete picture of Ivonescimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.